Le Lézard
Classified in: Health
Subject: FDA

SKINVIVEtm by JUVÉDERM® is Now FDA Approved, with Dr. Ran Rubinstein, MD selected as a Clinical Trainer


Dr. Ran Y. Rubinstein of Laser & Cosmetic Surgery Specialists announces FDA approval of SKINVIVEtm by JUVÉDERM®, the first HA intradermal microdroplet injection for skin by Allergan Aesthetics.

NEWBURGH, N.Y., May 23, 2023 /PRNewswire-PRWeb/ -- Laser & Cosmetic Surgery Specialists, the renowned cosmetic clinic headed by Dr. Ran Y. Rubinstein, is thrilled to announce the introduction of SKINVIVEtm by JUVÉDERM®, a groundbreaking development in aesthetic medicine. As of this month, SKINVIVEtm is now FDA approved and has been named the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin, developed by Allergan Aesthetics, an AbbVie company.

SKINVIVEtm by JUVÉDERM® is a revolutionary hyaluronic acid-based skin enhancement product formulated to improve skin hydration, elasticity, and smoothness. It has been approved by the FDA after rigorous testing and proven efficacy in replenishing and maintaining skin health. The product represents a significant breakthrough in aesthetic medicine, and Dr. Rubinstein is proud to have been selected as a clinical trainer for Allergan Aesthetics in this innovative procedure.

Dr. Rubinstein, an esteemed plastic surgeon with over 20 years of experience, will be at the forefront of bringing this state-of-the-art treatment to patients. He is recognized for his expertise and commitment to patient care and continues to contribute significantly to the field of aesthetic medicine.

"We are excited to provide this innovative solution to our patients," said Dr. Rubinstein. "The FDA approval of SKINVIVEtm by JUVÉDERM® stands as a testament to its effectiveness and safety. As a clinical trainer for Allergan Aesthetics, I am looking forward to teaching other physicians about the benefits of this treatment and helping them implement it in their practice."

Laser & Cosmetic Surgery Specialists, located in the heart of Newburgh, NY, has been serving clients with top-quality services and treatments for decades. The clinic prides itself on a personalized approach to aesthetic medicine, ensuring that each patient receives individualized care tailored to their unique needs. With the introduction of SKINVIVEtm, the clinic is furthering its mission to provide the latest and most effective treatments to its patients.

Dr. Rubinstein's role as a clinical trainer for Allergan Aesthetics reaffirms his status as a leader in the field. His clinic, Laser & Cosmetic Surgery Specialists, will serve as a hub for teaching and learning about the application of SKINVIVEtm.

"FDA approval of SKINVIVEtm is a leap forward in the field of cosmetic medicine," Dr. Rubinstein added. "Hyaluronic acid has long been recognized for its restorative properties and is a primary component of many successful dermal fillers. Now, we have an innovative way to deliver these benefits more effectively, improving skin quality with a quick, minimally invasive procedure."

About Dr. Ran Y. Rubinstein, MD

Dr. Ran Y. Rubinstein is a highly respected plastic surgeon known for his exceptional skills, innovative techniques, and commitment to patient care. With over two decades of experience in the field, he has built a reputation for delivering natural-looking results that enhance each patient's unique beauty. He specializes in facial plastic surgery. Dr. Rubinstein is board certified by the American Board of Facial Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.

Dr. Rubinstein's dedication to his patients extends beyond the surgical suite. He is an educator at heart, consistently sharing his expertise and insights with patients and fellow professionals alike. His role as a clinical trainer for Allergan Aesthetics, teaching the application of the newly approved SKINVIVEtm by JUVÉDERM®, is an extension of this commitment to knowledge sharing and ongoing professional development in the field of aesthetic medicine.

At Laser & Cosmetic Surgery Specialists, PC, Dr. Rubinstein's philosophy is deeply rooted in creating customized treatment plans for patients, ensuring that each individual's aesthetic goals are met with the utmost precision and care. His mastery of various aesthetic procedures, combined with his warm and compassionate approach, continues to set him apart in the field. His leadership and the addition of SKINVIVEtm by JUVÉDERM® to his practice further solidify his position as a pioneer in cosmetic surgery.

About Laser Cosmetic Surgery Specialists

Laser & Cosmetic Surgery Specialists, PC is a leading plastic surgery clinic situated in Newburgh, New York. It has garnered a reputation for excellence under the leadership of Dr. Ran Y. Rubinstein. The state-of-the-art facility specializes in cosmetic surgery of the face, body, and skin while also offering a range of non-surgical solutions, now including SKINVIVEtm by JUVÉDERM®.

The clinic is committed to delivering the highest standards of patient care and safety. Each patient receives a customized treatment plan designed to address their unique needs and aesthetic goals. The clinic's dedicated team ensures a comfortable and supportive environment, guiding patients through their journey toward enhanced self-confidence and well-being.

At Laser & Cosmetic Surgery Specialists, continuous innovation and education are paramount. The team stays abreast of the latest trends and technological advancements in the field of cosmetic surgery, ensuring that their patients have access to the most effective treatments. The inclusion of SKINVIVEtm by JUVÉDERM® highlights their commitment to leading-edge treatments and excellence in patient care.

Contact the Clinic

Patients interested in experiencing the cutting-edge SKINVIVEtm by JUVÉDERM® treatment are encouraged to reach out to Laser & Cosmetic Surgery Specialists to schedule a consultation. Dr. Rubinstein and his expert team are eager to assist patients in exploring the benefits of this transformative procedure.

In the pursuit of aesthetic excellence and patient satisfaction, Laser & Cosmetic Surgery Specialists continually strive to incorporate the latest advancements into their practice. With SKINVIVEtm by JUVÉDERM® now part of their service offerings, they look forward to serving their patients with an even higher standard of care.

For more information or to book a consultation, please visit http://www.yourfacemd.com or call the clinic directly at 845-863-1772.

Media Contact

Ran Y. Rubinstein, MD, Laser & Cosmetic Surgery Specialists, (845) 863-1772, [email protected]

 

SOURCE Laser & Cosmetic Surgery Specialists


These press releases may also interest you

at 16:15
Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate...

at 16:15
NovaBay® Pharmaceuticals, Inc. reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products...

at 16:15
OmniAb, Inc. today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. "The OmniAb team continued to make great progress this past quarter in advancing and expanding our...

at 16:15
Guardant Health, Inc. , a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $168.5 million for the first quarter of 2024, an increase of...

at 16:15
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. "The IMPALA-2 trial remains on-track...

at 16:14
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial...



News published on and distributed by: